Inclisiran Sodium is a siRNA-based antisense oligonucleotide therapeutic that functions as an RNA interference agent to treat atherosclerotic cardiovascular disease, ASCVD risk-equivalents, and heterozygous… Read more
Inclisiran Sodium is a siRNA-based antisense oligonucleotide therapeutic that functions as an RNA interference agent to treat atherosclerotic cardiovascular disease, ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia by lowering LDL cholesterol levels. Laboratories require high-quality reference standards for Inclisiran Sodium, including its active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds to support rigorous analytical testing and quality control protocols. These specialized reference materials are essential for accurate impurity profiling and method validation throughout the drug development and manufacturing lifecycle of this novel therapeutic. Utilizing these standards enables researchers and analytical chemists to reliably monitor the degradation products and metabolic pathway components of this complex small interfering RNA molecule, ensuring compliance with regulatory requirements and maintaining consistent product integrity for this lipid-lowering treatment.